Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SAB Biotherapeutics Inc (SABSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: SABSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.2% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio 0.09 | 1Y Target Price - |
Price to earnings Ratio 0.09 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.55 | 52 Weeks Range 0.02 - 0.15 | Updated Date 06/29/2025 |
52 Weeks Range 0.02 - 0.15 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -11193.25% |
Management Effectiveness
Return on Assets (TTM) -48.28% | Return on Equity (TTM) -92.35% |
Valuation
Trailing PE 0.09 | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6435987 |
Shares Outstanding - | Shares Floating 6435987 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
SAB Biotherapeutics Inc
Company Overview
History and Background
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies. Founded in 2014, it leverages its DiversitAbu2122 platform to produce fully-human polyclonal antibodies without human donors. The company has focused on infectious diseases, autoimmune diseases, and cancer.
Core Business Areas
- Therapeutic Development: SAB Biotherapeutics focuses on the research, development, and commercialization of novel immunotherapies derived from its DiversitAbu2122 platform. They are developing polyclonal antibody therapies for a range of diseases.
- DiversitAbu2122 Platform: The core of their business is the DiversitAbu2122 platform which produces human polyclonal antibodies in bovine. This platform is integral to the development of their therapeutic pipeline.
Leadership and Structure
Eddie J. Sullivan, PhD is the CEO, and the company has a management team focusing on research, development, and clinical operations. The company is structured around its platform technology and therapeutic pipeline.
Top Products and Market Share
Key Offerings
- SAB-185: A novel polyclonal antibody therapeutic for the treatment of COVID-19. SAB-185 was in Phase 3 clinical trials but did not meet its primary endpoint. Competitors include monoclonal antibody therapies from Regeneron and Eli Lilly, as well as antiviral treatments like Paxlovid from Pfizer. No specific market share data available as it is not yet approved.
- SAB-142: A polyclonal antibody therapy for influenza. Currently in preclinical stages. Competitors include influenza vaccines from various manufacturers such as Seqirus, Sanofi, and GSK and antiviral treatments like Tamiflu. No specific market share data available as it is not yet approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory oversight. Focus areas include infectious diseases, oncology, and autoimmune disorders, with increasing emphasis on novel immunotherapies.
Positioning
SAB Biotherapeutics is positioned as an innovator in the polyclonal antibody space, leveraging its DiversitAbu2122 platform to develop novel therapies. Its competitive advantage lies in the potential to produce fully human polyclonal antibodies at scale and without human donors.
Total Addressable Market (TAM)
The total addressable market depends on the specific indications targeted. The global market for antibody therapeutics is substantial, projected to reach hundreds of billions of dollars. SAB's TAM is dependent on their approved indications. The DiversitAbu2122 platform allows them to develop therapies that can quickly respond to pandemics.
Upturn SWOT Analysis
Strengths
- Novel DiversitAbu2122 platform
- Potential for scalable antibody production
- Ability to produce fully-human polyclonal antibodies without human donors
Weaknesses
- Limited number of commercially available products
- Reliance on a single technology platform
- High cash burn rate
Opportunities
- Expanding the therapeutic pipeline to address unmet medical needs
- Strategic partnerships with larger pharmaceutical companies
- Government funding for pandemic preparedness initiatives
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established biopharmaceutical companies
Competitors and Market Share
Key Competitors
- REGN
- LLY
- PFE
- GSK
Competitive Landscape
SAB Biotherapeutics faces significant competition from large pharmaceutical companies with established pipelines and commercial infrastructure. SAB's competitive advantage lies in its novel DiversitAbu2122 platform but needs more funding.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily focused on advancing its DiversitAbu2122 platform and clinical programs. Growth was dependent on securing funding and achieving clinical milestones.
Future Projections: Future growth depends on the success of their pipeline, expansion of their DiversitAbu2122 platform, and new partnerships. Growth prospects are tied to the successful commercialization of its therapies.
Recent Initiatives: Focusing on developing and testing their pipeline products and also forming new partnerships.
Summary
SAB Biotherapeutics has an innovative platform for producing polyclonal antibodies. However, past clinical trial failures, high cash burn rate, and delisting raise concerns. Their success relies heavily on clinical pipeline advancement and securing strategic partnerships. The company's novel approach offers potential in the immunotherapy space, but its financial and operational challenges need to be addressed. Recent initiatives suggest a refocusing on platform applications and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (Prior to delisting)
- Press Releases
- Analyst Reports
- Third party Financial databases
Disclaimers:
The information provided is based on publicly available data and represents a snapshot at a specific point in time. Financial data may be outdated or incomplete due to the company being privately owned. This analysis is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SAB Biotherapeutics Inc
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-02-09 | CEO & Executive Chairman Mr. Samuel J. Reich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.